Jeffrey D. Bradley, MD, on NSCLC: Results of the RTOG 0617 Trial

2017 ASTRO Annual Meeting
Tweet this page

Jeffrey D. Bradley, MD, of Washington University School of Medicine, discusses long-term phase III findings on standard-dose vs high-dose conformal chemoradiation therapy with or without cetuximab for stage III non–small cell lung cancer (Abstract 227).

Advertisement

Advertisement



Advertisement